ERP Insights >> Magazine >> March - 2016 issue
Technology Innovations in Healthcare
Author : Naz Haji, Senior Vice President & Head, Quintiles India
Sunday, April 3, 2016
Overall, advancements in technology are playing an increasingly important role in our understanding and management of healthcare and disease in an industry (life sciences) that is highly complex and regulated. These advancements are also impacting the way clinical trials are being conducted and managed with technology driving end-to-end customer value, incorporating design, execution, engagement and commercialization within the drug development process.
Drug development is dependent upon the availability of high quality data to collaborate and make informed decisions at every step of the way during the evolution of a product or treatment. At Quintiles, we have access to 61 million de-identified electronic health records used in trial design from more than 175,000 providers, since 2004. We deal with peta bytes of de-identified patient data aggregated into illustrative datasets in different therapeutic areas of varied complexities that include clinical research operations, laboratory, ECG and imaging data to genome sequencing data.
One of the key challenges is how to use data to deliver insightful information that will lead to faster decision making, and ultimately more accessible and affordable healthcare. Two examples of how Quintiles is doing this to deliver value in clinical trials are Quintiles Infosario, and our Risk-Based Monitoring (RBM) offering.
With the Quintiles Infosario platform, Quintiles has developed the technology to take data from multiple source systems and integrate, synchronize and normalize and present this data in near real-time. This creates a seamless integration of data, therapeutic expertise and clinical trial processes in a system that provides data transparency, optimized workflows, and real time insights into patient, study/site and programme activities. Powering this is the Infosario Data Factory - the clearinghouse and data hub for clinical and commercial data for the industry, supporting clinical development and integrated health analytics. The platform is designed to deliver accurate and consistent data insights, to enhance enterprise knowledge management, improve business insights and decision-making, and increase operational efficiencies. We have recently launched the Infosario One Mobile App which provides mobile access to critical clinical trial information. Using the mobile app, key stakeholders in the drug development process can conveniently access site start-up, recruitment and compliance information as well as status updates on data queries and project milestones.
Risk-based monitoring (RBM) has become a cornerstone of innovative trial execution. With our Data Driven Trial Execution (DTE) led by RBM, we use data-driven processes and insights to drive faster, more informed decisions. We are the RBM market leader currently engaged in more than 130 studies using RBM processes and policies, across more than 26,000 sites and 260,000 patients. We have seen our RBM model deliver value in several areas including ability to impact clinical monitoring costs, decreased time to analysis-ready data, increased quality, reduced risk, and the ability to impact medical monitoring.
More recently, Quintiles contributed open-source code enhancements to Apple's ResearchKit framework which was designed to make it easy for researchers to gather data more frequently and more accurately from research participants using iPhone apps. The Quintiles-contributed enhancements to the ResearchKit framework provide developers with extensions that support additional capabilities which, in turn, will allow them to create more sophisticated application experiences.
Mobile and wearable technologies also present an exciting opportunity for the industry. The evolution of wearable technology goes beyond just the gadget itself and encompasses the data it collects, the significance of this data, and how the data is interpreted. Organizations that are able to integrate all of this seamlessly will be able to harness the power of data across the drug development continuum to improve a customer's probability of success.
We are clearly only at the beginnings of understanding what we can do with big data, and we will, in the future, see more about how we can link health data with social data, so we don't just understand impact on patient outcomes and the healthcare economy, but also on the productivity of the population. At the same time, there will be a move to more prescriptive analytics, using data not just to capture behavior patterns, but to actually promote changes. In a sense, it will mean turning the agenda around, so it's less about understanding what is happening, and more about how we use the data to drive behavior change.
Technology Innovations in Healthcare
Author : Naz Haji, Senior Vice President & Head, Quintiles India
Sunday, April 3, 2016
Overall, advancements in technology are playing an increasingly important role in our understanding and management of healthcare and disease in an industry (life sciences) that is highly complex and regulated. These advancements are also impacting the way clinical trials are being conducted and managed with technology driving end-to-end customer value, incorporating design, execution, engagement and commercialization within the drug development process.
Drug development is dependent upon the availability of high quality data to collaborate and make informed decisions at every step of the way during the evolution of a product or treatment. At Quintiles, we have access to 61 million de-identified electronic health records used in trial design from more than 175,000 providers, since 2004. We deal with peta bytes of de-identified patient data aggregated into illustrative datasets in different therapeutic areas of varied complexities that include clinical research operations, laboratory, ECG and imaging data to genome sequencing data.
One of the key challenges is how to use data to deliver insightful information that will lead to faster decision making, and ultimately more accessible and affordable healthcare. Two examples of how Quintiles is doing this to deliver value in clinical trials are Quintiles Infosario, and our Risk-Based Monitoring (RBM) offering.
With the Quintiles Infosario platform, Quintiles has developed the technology to take data from multiple source systems and integrate, synchronize and normalize and present this data in near real-time. This creates a seamless integration of data, therapeutic expertise and clinical trial processes in a system that provides data transparency, optimized workflows, and real time insights into patient, study/site and programme activities. Powering this is the Infosario Data Factory - the clearinghouse and data hub for clinical and commercial data for the industry, supporting clinical development and integrated health analytics. The platform is designed to deliver accurate and consistent data insights, to enhance enterprise knowledge management, improve business insights and decision-making, and increase operational efficiencies. We have recently launched the Infosario One Mobile App which provides mobile access to critical clinical trial information. Using the mobile app, key stakeholders in the drug development process can conveniently access site start-up, recruitment and compliance information as well as status updates on data queries and project milestones.
Risk-based monitoring (RBM) has become a cornerstone of innovative trial execution. With our Data Driven Trial Execution (DTE) led by RBM, we use data-driven processes and insights to drive faster, more informed decisions. We are the RBM market leader currently engaged in more than 130 studies using RBM processes and policies, across more than 26,000 sites and 260,000 patients. We have seen our RBM model deliver value in several areas including ability to impact clinical monitoring costs, decreased time to analysis-ready data, increased quality, reduced risk, and the ability to impact medical monitoring.
More recently, Quintiles contributed open-source code enhancements to Apple's ResearchKit framework which was designed to make it easy for researchers to gather data more frequently and more accurately from research participants using iPhone apps. The Quintiles-contributed enhancements to the ResearchKit framework provide developers with extensions that support additional capabilities which, in turn, will allow them to create more sophisticated application experiences.
Mobile and wearable technologies also present an exciting opportunity for the industry. The evolution of wearable technology goes beyond just the gadget itself and encompasses the data it collects, the significance of this data, and how the data is interpreted. Organizations that are able to integrate all of this seamlessly will be able to harness the power of data across the drug development continuum to improve a customer's probability of success.
We are clearly only at the beginnings of understanding what we can do with big data, and we will, in the future, see more about how we can link health data with social data, so we don't just understand impact on patient outcomes and the healthcare economy, but also on the productivity of the population. At the same time, there will be a move to more prescriptive analytics, using data not just to capture behavior patterns, but to actually promote changes. In a sense, it will mean turning the agenda around, so it's less about understanding what is happening, and more about how we use the data to drive behavior change.
Drug development is dependent upon the availability of high quality data to collaborate and make informed decisions at every step of the way during the evolution of a product or treatment. At Quintiles, we have access to 61 million de-identified electronic health records used in trial design from more than 175,000 providers, since 2004. We deal with peta bytes of de-identified patient data aggregated into illustrative datasets in different therapeutic areas of varied complexities that include clinical research operations, laboratory, ECG and imaging data to genome sequencing data.
One of the key challenges is how to use data to deliver insightful information that will lead to faster decision making, and ultimately more accessible and affordable healthcare. Two examples of how Quintiles is doing this to deliver value in clinical trials are Quintiles Infosario, and our Risk-Based Monitoring (RBM) offering.
With the Quintiles Infosario platform, Quintiles has developed the technology to take data from multiple source systems and integrate, synchronize and normalize and present this data in near real-time. This creates a seamless integration of data, therapeutic expertise and clinical trial processes in a system that provides data transparency, optimized workflows, and real time insights into patient, study/site and programme activities. Powering this is the Infosario Data Factory - the clearinghouse and data hub for clinical and commercial data for the industry, supporting clinical development and integrated health analytics. The platform is designed to deliver accurate and consistent data insights, to enhance enterprise knowledge management, improve business insights and decision-making, and increase operational efficiencies. We have recently launched the Infosario One Mobile App which provides mobile access to critical clinical trial information. Using the mobile app, key stakeholders in the drug development process can conveniently access site start-up, recruitment and compliance information as well as status updates on data queries and project milestones.
Risk-based monitoring (RBM) has become a cornerstone of innovative trial execution. With our Data Driven Trial Execution (DTE) led by RBM, we use data-driven processes and insights to drive faster, more informed decisions. We are the RBM market leader currently engaged in more than 130 studies using RBM processes and policies, across more than 26,000 sites and 260,000 patients. We have seen our RBM model deliver value in several areas including ability to impact clinical monitoring costs, decreased time to analysis-ready data, increased quality, reduced risk, and the ability to impact medical monitoring.
More recently, Quintiles contributed open-source code enhancements to Apple's ResearchKit framework which was designed to make it easy for researchers to gather data more frequently and more accurately from research participants using iPhone apps. The Quintiles-contributed enhancements to the ResearchKit framework provide developers with extensions that support additional capabilities which, in turn, will allow them to create more sophisticated application experiences.
Mobile and wearable technologies also present an exciting opportunity for the industry. The evolution of wearable technology goes beyond just the gadget itself and encompasses the data it collects, the significance of this data, and how the data is interpreted. Organizations that are able to integrate all of this seamlessly will be able to harness the power of data across the drug development continuum to improve a customer's probability of success.
We are clearly only at the beginnings of understanding what we can do with big data, and we will, in the future, see more about how we can link health data with social data, so we don't just understand impact on patient outcomes and the healthcare economy, but also on the productivity of the population. At the same time, there will be a move to more prescriptive analytics, using data not just to capture behavior patterns, but to actually promote changes. In a sense, it will mean turning the agenda around, so it's less about understanding what is happening, and more about how we use the data to drive behavior change.
